Showing results (1221-1230 of 2,335) with videos related to
Sort By:
Pageof 234
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 20, 2020
Ideas and Innovations to Improve the Otolaryngology-Head and Neck Surgery Residency Application and Selection ProcessParsa P Salehi, Alyssa Heiser, Pauniz Salehi, et al.Pediatric Cardiology|December 23, 2022
Remote Care Adoption in Underserved Congenital Heart Disease Patients During the COVID-19 EraRuth M Vaughan, Judson A Moore, Jasmine S Moreno, et al.The European Respiratory Journal|February 8, 2008
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trialM A Judson, R P Baughman, U Costabel, et al.Journal of the American College of Cardiology|January 14, 2014
Outcomes of acute type a dissection repair before and after implementation of a multidisciplinary thoracic aortic surgery programNicholas D Andersen, Asvin M Ganapathi, Jennifer M Hanna, et al.JMIR Aging|May 26, 2023
Patient Perceptions of e-Visits: Qualitative Study of Older Adults to Inform Health System ImplementationTimothy J Judson, Meera Subash, James D Harrison, et al.Clinical Sarcoma Research|May 6, 2016
UK guidelines for the management of bone sarcomasCraig Gerrand, Nick Athanasou, Bernadette Brennan, et al.British Journal of Cancer|February 1, 1991
Phase II trial of trimelamol in refractory ovarian cancerI R Judson, A H Calvert, M E Gore, et al.British Journal of Cancer|November 27, 1999
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignanciesM Brada, I Judson, P Beale, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|December 8, 2017
High-Throughput H295R Steroidogenesis Assay: Utility as an Alternative and a Statistical Approach to Characterize Effects on SteroidogenesisDerik E Haggard, Agnes L Karmaus, Matthew T Martin, et al.British Journal of Cancer|October 1, 1994
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanomaN M Bleehen, A H Calvert, S M Lee, et al.Pageof 234